CA2370007A1 - Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases - Google Patents

Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases Download PDF

Info

Publication number
CA2370007A1
CA2370007A1 CA002370007A CA2370007A CA2370007A1 CA 2370007 A1 CA2370007 A1 CA 2370007A1 CA 002370007 A CA002370007 A CA 002370007A CA 2370007 A CA2370007 A CA 2370007A CA 2370007 A1 CA2370007 A1 CA 2370007A1
Authority
CA
Canada
Prior art keywords
geldanamycin
chemical compound
hsp
kinases
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370007A
Other languages
English (en)
French (fr)
Inventor
Neal Rosen
Scott D. Kuduk
Samuel J. Danishefsky
Furzhong F. Zheng
Laura Sepp-Lorenzino
Ouathek Ouerfelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370007A1 publication Critical patent/CA2370007A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CA002370007A 1999-04-09 2000-04-07 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases Abandoned CA2370007A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12859399P 1999-04-09 1999-04-09
US60/128,593 1999-04-09
PCT/US2000/009512 WO2000061578A1 (en) 1999-04-09 2000-04-07 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases

Publications (1)

Publication Number Publication Date
CA2370007A1 true CA2370007A1 (en) 2000-10-19

Family

ID=22436066

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370007A Abandoned CA2370007A1 (en) 1999-04-09 2000-04-07 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases

Country Status (6)

Country Link
US (1) US7271160B2 (https=)
EP (1) EP1169319A4 (https=)
JP (1) JP2002541255A (https=)
AU (1) AU769235B2 (https=)
CA (1) CA2370007A1 (https=)
WO (1) WO2000061578A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4093799A (en) 1998-05-22 1999-12-13 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
WO2001035978A1 (en) 1999-11-19 2001-05-25 The Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
ATE526019T1 (de) 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
DE60120427D1 (de) 2000-08-25 2006-07-20 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2002094196A2 (en) 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
CA2460498A1 (en) 2001-09-24 2003-04-03 Conforma Therapeutics Corporation Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
GB0202871D0 (en) * 2002-02-07 2002-03-27 Cancer Res Ventures Ltd Assays,methods and means
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
CA2572318A1 (en) * 2004-07-02 2006-01-12 Neutec Pharma Plc Treatment of cancer
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
AU2006230447A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2010028389A1 (en) * 2008-09-08 2010-03-11 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
JP6266506B2 (ja) 2011-04-05 2018-01-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
US9446175B2 (en) 2011-06-03 2016-09-20 Yale University Compositions and methods for treating and preventing neointimal stenosis
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
KR20200016874A (ko) 2017-06-20 2020-02-17 마드리갈 파마슈티칼스 인코포레이티드 표적화 치료제를 포함하는 병용 요법
CA3067572A1 (en) 2017-06-20 2018-12-27 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
CN117700313B (zh) * 2023-12-14 2025-02-14 怒江绿色香料产业研究院 一种羟基十四烯醛及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111469A (en) * 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
US5650430A (en) 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
CA2052907A1 (en) * 1990-10-11 1992-04-12 Joseph P. Vacca Hiv protease inhibitors having symmetrical structure
JP2794342B2 (ja) * 1993-06-29 1998-09-03 ファイザー・インク． 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
KR19990076764A (ko) 1996-10-25 1999-10-15 히라타 다다시 래디시콜 유도체
CA2287387C (en) * 1997-05-14 2010-02-16 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Also Published As

Publication number Publication date
JP2002541255A (ja) 2002-12-03
AU4223500A (en) 2000-11-14
EP1169319A1 (en) 2002-01-09
AU769235B2 (en) 2004-01-22
EP1169319A4 (en) 2005-02-09
US7271160B2 (en) 2007-09-18
US20020045570A1 (en) 2002-04-18
WO2000061578A1 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
AU769235B2 (en) Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
CA2026147C (en) Cytotoxic agents comprising maytansinoids and their therapeutic use
KR960015398B1 (ko) 신규의 링커를 갖는 안트라사이클린 면역결합체 및 그의 제조방법
TWI662968B (zh) 配體－細胞毒性藥物偶聯物、其製備方法及其應用
EP3783025A1 (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
US5911995A (en) EGF-genistein conjugates for the treatment of cancer
US6391913B1 (en) Derivatives of paclitaxel, method for producing same and uses thereof
CA3198788A1 (en) Camptothecine antibody-drug conjugates and methods of use thereof
Li et al. Development of a novel EGFR-targeting antibody-drug conjugate for pancreatic cancer therapy
JP2018507844A (ja) 抗体薬物コンジュゲート
HU208161B (en) Process for producing cytotoxic active ingredient - antibody conjugates and pharmaceutical compositions
US20100029758A1 (en) Derivatives of isoflavones
US20230134986A1 (en) Glucose triptolide conjugates and uses thereof
CA3210473A1 (en) Branched linkers for antibody-drug conjugates and methods of use thereof
Milazzo et al. ErbB2 targeted epigenetic modulation: anti-tumor efficacy of the ADC trastuzumab-HDACi ST8176AA1
US20240398823A1 (en) Dual inhibitor of histone deacetylase 6 and heat shock protein 90
RU2455990C2 (ru) Фармацевтическое соединение
Li et al. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy
US20060052312A1 (en) Paclitaxel hybrid derivatives
CN116036303A (zh) 一种抗体-药物偶联物及其制备方法和应用
US7238682B1 (en) Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases
KR102561285B1 (ko) 신규 her3 억제제 및 이를 포함하는 암 예방 또는 치료용약학 조성물
US20040115209A1 (en) Compound targeted for specific cells with reduced systemic toxicity
Puspitasari et al. Conjugation of cetuximab–puromycin and its target-specific effect on triple negative breast cancer cell lines
WO2025113659A1 (zh) 三糖连接子，包含三糖连接子的连接子-负载物和糖链重塑的抗体偶联药物，其制备方法和用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued